ArticleBiomaterials2015
Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer.
Article in Biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Peritoneal chemotherapy delivery systems for ovarian cancer treatment: systematic review of animal models.Frontiers in oncology · 2024Pooled it
- Evaluation of Different Commercial Sealing Hemostatic Patches for Their Selection as Reservoirs for Localized Intraperitoneal Chemotherapy.ACS pharmacology & translational science · 2025Article
- Enzyme-Empowered "Two Birds with One Stone" Strategy for Amplifying Tumor Apoptosis and Metabolic Clearance.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Nanoplatforms: The future of oral cancer treatment.Health science reports · 2023Article
- Recent developments in natural biopolymer based drug delivery systems.RSC advances · 2023Review
- Facile Synthesis and X-ray Attenuation Properties of Ultrasmall Platinum Nanoparticles Grafted with Three Types of Hydrophilic Polymers.Nanomaterials (Basel, Switzerland) · 2023Article
- Flexible polymeric patch based nanotherapeutics against non-cancer therapy.Bioactive materials · 2022Review
- Hydrogels for localized chemotherapy of liver cancer: a possible strategy for improved and safe liver cancer treatment.Drug delivery · 2022Article
- In situ gelatinase-responsive and thermosensitive nanocomplex for local therapy of gastric cancer with peritoneal metastasis.Materials today. Bio · 2022Article
- Synergistic enhancement of immunological responses triggered by hyperthermia sensitive Pt NPsBioactive materials · 2022Article
- Research progress in the application ofDrug delivery · 2020Review
- Tuning the Physicochemical Characteristics of Particle-Based Carriers for Intraperitoneal Local Chemotherapy.Pharmaceutical research · 2020Review
- Review
- Heterotargeted Nanococktail with Traceless Linkers for Eradicating Cancer.Advanced functional materials · 2019Article
- Recent advances in metallopolymer-based drug delivery systems.RSC advances · 2019Review
- Strategies for Hyaluronic Acid-Based Hydrogel Design in Drug Delivery.Pharmaceutics · 2019Review
- Developing Body-Components-Based Theranostic Nanoparticles for Targeting Ovarian Cancer.Pharmaceutics · 2019Article
- Slow-Release Formulation of Cowpea Mosaic Virus for In Situ Vaccine Delivery to Treat Ovarian Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2018Article
- Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly.Acta biomaterialia · 2018Article
- Nanogels for Pharmaceutical and Biomedical Applications and Their Fabrication Using 3D Printing Technologies.Materials (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
Abstract
Intraperitoneal (IP) chemotherapy is a promising post-surgical therapy of solid carcinomas confined within the peritoneal cavity, with potential benefits in locoregional and systemic management of residual tumors. In this study, we intended to increase local retention of platinum in the peritoneal cavity over a prolonged period of time using a nanoparticle form of platinum and an in-situ crosslinkable hyaluronic acid gel. Hyaluronic acid was chosen as a carrier due to the biocompatibility and biodegradability. We confirmed a sustained release of platinum from the nanoparticles (PtNPs) and nanoparticle/gel hybrid (PtNP/gel), receptor-mediated endocytosis of PtNPs, and retention of the gel in the peritoneal cavity over 4 weeks: conditions desirable for a prolonged local delivery of platinum. However, PtNPs and PtNP/gel did not show a greater anti-tumor efficacy than CDDP solution administered at the same dose but rather caused a slight increase in tumor burdens at later time points, which suggests a potential involvement of empty carriers and degradation products in the growth of residual tumors. This study alerts that although several materials considered biocompatible and safe are used as drug carriers, they may have unwanted biological effects on the residual targets once the drug is exhausted; therefore, more attention should be paid to the selection of drug carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.